PMID- 35238169 OWN - NLM STAT- MEDLINE DCOM- 20220920 LR - 20220920 IS - 1743-7563 (Electronic) IS - 1743-7555 (Linking) VI - 18 IP - 5 DP - 2022 Oct TI - A new prognostic model including platelet/lymphocyte ratio and International Prognostic Score 3 for freedom from progression in patients with previously untreated advanced classical Hodgkin lymphoma. PG - e486-e494 LID - 10.1111/ajco.13770 [doi] AB - PURPOSE: We aimed to develop a new risk stratification tool to predict freedom from progression (FFP) for newly diagnosed advanced classical Hodgkin lymphoma (cHL). METHODS: We collected data from 386 patients with advanced cHL diagnosed between December 8, 2000 and October 29, 2018, and treated with curative intent with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) or an ABVD-equivalent regimen. Cases were randomly divided into training and validation cohorts at a ratio of 7:3. The new model was constructed based on the results of Cox proportional hazards model in the training cohort. Comparisons of discrimination between the new model and other models in the training and validation cohorts for FFP prediction were measured by time-dependent area under curve (tAUC) and Harrell's C-index. Calibration plots were constructed to compare the consistency between the predicted and observed estimates of survival probability for the new model in the training and validation cohorts. RESULTS: The new model (IPSPLR) composed of International Prognostic Score (IPS)-3 and platelet/lymphocyte ratio (PLR) provided four distinct risk groups. The IPSPLR showed better discriminative ability when compared with IPS-3 and IPS-7. The AUC of IPSPLR was consistently higher than that of IPS-3 and IPS-7 between 12 and 120 months. The C-index of the IPSPLR was higher than that of IPS-7 and IPS-3. The calibration plots showed an excellent agreement between the IPSPLR-predicted and observed estimates of 5-year FFP. CONCLUSION: The IPSPLR is an easily used tool for FFP prediction for newly diagnosed advanced cHL. Validation of this tool in other large datasets is needed. CI - (c) 2022 John Wiley & Sons Australia, Ltd. FAU - Tao, Yunxia AU - Tao Y AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China. FAU - Chen, Haizhu AU - Chen H AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China. FAU - Zhou, Yu AU - Zhou Y AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China. FAU - He, Xiaohu AU - He X AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China. FAU - Qin, Yan AU - Qin Y AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China. FAU - Liu, Peng AU - Liu P AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China. FAU - Zhou, Shengyu AU - Zhou S AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China. FAU - Yang, Jianliang AU - Yang J AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China. FAU - Zhou, Liqiang AU - Zhou L AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China. FAU - Zhang, Changgong AU - Zhang C AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China. FAU - Yang, Sheng AU - Yang S AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China. FAU - Gui, Lin AU - Gui L AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China. FAU - Shi, Yuankai AU - Shi Y AUID- ORCID: 0000-0002-8685-6744 AD - Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China. LA - eng PT - Journal Article DEP - 20220303 PL - Australia TA - Asia Pac J Clin Oncol JT - Asia-Pacific journal of clinical oncology JID - 101241430 RN - 11056-06-7 (Bleomycin) RN - 5V9KLZ54CY (Vinblastine) RN - 7GR28W0FJI (Dacarbazine) RN - 80168379AG (Doxorubicin) SB - IM MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Bleomycin/therapeutic use MH - Dacarbazine/therapeutic use MH - Doxorubicin/therapeutic use MH - Freedom MH - *Hodgkin Disease/drug therapy MH - Humans MH - Lymphocytes/pathology MH - Neoplasm Staging MH - Prognosis MH - Vinblastine/therapeutic use OTO - NOTNLM OT - ABVD OT - International Prognostic Score OT - classical Hodgkin lymphoma OT - freedom free progression OT - platelet/lymphocyte ratio EDAT- 2022/03/04 06:00 MHDA- 2022/09/21 06:00 CRDT- 2022/03/03 05:40 PHST- 2021/09/01 00:00 [received] PHST- 2022/02/06 00:00 [accepted] PHST- 2022/03/04 06:00 [pubmed] PHST- 2022/09/21 06:00 [medline] PHST- 2022/03/03 05:40 [entrez] AID - 10.1111/ajco.13770 [doi] PST - ppublish SO - Asia Pac J Clin Oncol. 2022 Oct;18(5):e486-e494. doi: 10.1111/ajco.13770. Epub 2022 Mar 3.